Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Lifetime Exposure to Welding Fumes and Risk of Some Rare Cancers.
Kendzia B, Kaerlev L, Ahrens W, Merletti F, Eriksson M, Guénel P, Lynge E, Costa-Pereira A, Morales Suárez-Varela M, Jöckel KH, Stang A, Behrens T. Kendzia B, et al. Am J Epidemiol. 2022 Sep 28;191(10):1753-1765. doi: 10.1093/aje/kwac123. Am J Epidemiol. 2022. PMID: 35872594
We investigated the association between exposure to welding fumes and the risk of biliary tract, male breast, bone, and thymus cancer, as well as cancer of the small intestine, eye melanoma, and mycosis fungoides, among men in a European, multicenter case-control st …
We investigated the association between exposure to welding fumes and the risk of biliary tract, male breast, bone, and thymus can …
Sunitinib effective for rare thymus cancer.
[No authors listed] [No authors listed] Cancer Discov. 2015 Apr;5(4):340. doi: 10.1158/2159-8290.CD-NB2015-017. Epub 2015 Feb 13. Cancer Discov. 2015. PMID: 25680712
In a phase II trial, the tyrosine kinase inhibitor sunitinib was effective in previously treated patients with thymic carcinoma, offering the first viable second-line treatment option for patients with this rare and aggressive form of thymus cancer....
In a phase II trial, the tyrosine kinase inhibitor sunitinib was effective in previously treated patients with thymic carcinoma, offe …
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R. Wicki A, et al. Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13. Eur J Cancer. 2018. PMID: 29660598 Clinical Trial.
PK shows fast absorption (T(max) 1-2 h) and dose proportionality for C(max) and area under the curve. A partial response in a patient with metastatic thymus cancer, 24% disease volume reduction in a patient with sinonasal cancer and stable disease for more than 16 w …
PK shows fast absorption (T(max) 1-2 h) and dose proportionality for C(max) and area under the curve. A partial response in a patient with m …
De novo hepatocellular carcinoma in a non-cirrhotic allograft 27 years after liver transplantation: A case report.
El-Domiaty N, Saliba F, Sebagh M, Salloum C, Vibert E, Azoulay D, Hamelin J, Cherqui D, Adam R, Samuel D. El-Domiaty N, et al. Am J Transplant. 2021 May;21(5):1953-1958. doi: 10.1111/ajt.16476. Epub 2021 Jan 23. Am J Transplant. 2021. PMID: 33382179 Free article.
Pretransplant assessment and explant liver pathology revealed no tumor. He developed an 8 cm mediastinal thymus cancer in 2014, a chronic myeloid leukemia in 2015 and a 16 mm renal cell carcinoma in 2017. ...
Pretransplant assessment and explant liver pathology revealed no tumor. He developed an 8 cm mediastinal thymus cancer in 2014 …